New Jersey A5062 mandates health insurance and Medicaid coverage for diagnostic testing and treatments to slow Alzheimer's disease progression.

New Jersey A5062 requires health insurance and Medicaid to cover diagnostic testing and treatments for Alzheimer's disease and related disorders, as approved by the U.S. Food and Drug Administration and prescribed by a physician. The bill ensures these treatments are not subject to step therapy requirements and must be covered to the same extent as other conditions. It applies to various health insurance plans and the Medicaid program in New Jersey.

New Jersey A5062 mandates health insurance and Medicaid coverage for diagnostic testing and treatments to slow Alzheimer's disease progression.

New Jersey A5062 requires health insurance and Medicaid to cover diagnostic testing and treatments for Alzheimer's disease and related disorders, as approved by the U.S. Food and Drug Administration and prescribed by a physician. The bill ensures these treatments are not subject to step therapy requirements and must be covered to the same extent as other conditions. It applies to various health insurance plans and the Medicaid program in New Jersey.